Cite
Okuhara S, Umemura T, Joshita S, et al. Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatol Res. 2014;44(10):E172-80doi: 10.1111/hepr.12287.
Okuhara, S., Umemura, T., Joshita, S., Shibata, S., Kimura, T., Morita, S., Komatsu, M., Matsumoto, A., Yoshizawa, K., Katsuyama, Y., Ota, M., & Tanaka, E. (2014). Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatology research : the official journal of the Japan Society of Hepatology, 44(10), E172-80. https://doi.org/10.1111/hepr.12287
Okuhara, Sadahisa, et al. "Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B." Hepatology research : the official journal of the Japan Society of Hepatology vol. 44,10 (2014): E172-80. doi: https://doi.org/10.1111/hepr.12287
Okuhara S, Umemura T, Joshita S, Shibata S, Kimura T, Morita S, Komatsu M, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, Tanaka E. Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatol Res. 2014 Oct;44(10):E172-80. doi: 10.1111/hepr.12287. Epub 2014 Jan 26. PMID: 24308754.
Copy
Download .nbib